Retham Technologies (Milwaukee) is a diagnostics company focused on developing clinically needed blood tests. For its initial product line, the company seeks to revolutionize the diagnosis and management of Heparin induced thrombocytopenia (HIT), with its patented HITDx assay.
Retham was cofounded by Dr. Anand Padmanabhan and Daniel Sem in 2017, based on groundbreaking research Dr. Padmanabhan conducted when he was at Blood Center of Wisconsin. The clinical diagnostic assay the company is developing provides more reliable results in less time (< 1 day vs. 3 days) than the current market-dominant test for HIT, and will prevent many deaths or amputations from this autoimmune reaction that nearly 1% of patients have to Heparin treatment. Retham expects its HITDx assay to be on the market and in clinical labs by 2023.